DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 06 · Volume 21 · November 1988 DOI: 10.1055/s-002-10153

Introduction

  • 263
    Müller-Oerlinghausen, B.; Pflug, B.:

    15th AGNP-Symposium, Nuremberg, 1987

    • Psychotrophic Drug Utilization

  • 264
    Netter, Petra:

    Prescription of Drugs as Related to Environmental and Organismic Determinants of Drug Action

  • 266
    Linden, M.:

    Individual Aspects of Physician and Patient, and their Impact on the Prescription of Psychotropic Medication

  • 268
    Bauer, M.; Scherer, J.; Strauß, A.:

    Is Psychopharmacotherapy Symptom or Diagnosis Directed?

  • 270
    Barnas, C.; Fleischhacker, W. W.; Stuppäck, C.:

    Utilisation of Benzodiazepines in a University Hospital

  • 272
    König, W.; Rissom, R.; Kalfoglu, G.; Stein, A.; Reimer, F.:

    Long-term Therapy of Affective Disorders: Monotherapy or Polypharmacy?

  • 274
    Schmidt, St.; Ludwig, W.; Seibold, S.; Greil, W.:

    Prophylactic Lithium Treatment: Treatment Response, and Patient Attitudes toward Illness and Treatment

  • 276
    Koch, R.; Strauss, A.:

    The Course of Neuroleptic and Antidepressant Treatment in Severe Depressive Illness

  • 293
    Bürke, H.; Grohmann, R.; Rüther, E.:

    Drug Surveillance / Drug Monitoring in Psychiatric Out-Patient Treatment: Prescription of Psychotropic Drugs, Diagnoses and Adverse Drug Reaction - 3 Years

  • 295
    Classen, W.; Laux, G.:

    Sensorimotor and Cognitive Performance of Schizophrenic Inpatients Treated with Haloperidol, Flupenthixol, or Clozapine

  • 298
    Strauss, W. H.; Klieser, E.; Luethcke, H.:

    Dyscognitive Syndromes in Neuroleptic Therapy

  • 300
    Kuny, S.; Binswanger, U.:

    Ionized Calcium and Neuroleptic-induced Extrapyramidal Symptoms

  • 302
    Wagner, B.; Wolf, G. K.; Ulmar, G.:

    Does Smoking Reduce the Risk of Neuroleptic Parkinsonoids?

  • 304
    Möller, H. J.; Meier, K.; Wernicke, T.:

    Empirical Investigation on the Risk of Agranulocytosis/Leucopenia under Medication with Antidepressants

  • 306
    Sassim, N.; Grohmann, R.:

    Adverse Drug Reactions with Clozapine and Simultaneous Application of Benzodiazepines

  • 308
    Tegeler, J.; Strauss, W. H.; Lüthcke, H.; Bertling, R.:

    Cognitive Functions in Schizophrenic Patients with Tardive Dyskinesia

  • 310
    Kalserauer, Ch. H.; Komhuber, J.; Komhuber, A. W.; Bauer, K.:

    Alcohol Consumption, Blood-Cerebrospinal Fluid Barrier,and Guillain-Barré Syndrome

  • 314
    Havemann, Ursula:

    Does Individually Different Sensitivity to Dopaminergic Stimulation Determine the Degree of Tolerance and Dependence to Opioids?

  • 317
    Kuschinksy, K.; Möller, H.-G.; Novak, K.; Walter, S.:

    Conditioning of Signs of a Dopaminergic Stimulation in Rats

  • 319
    Rick-Brand, Sabine; Müller, W. E.:

    Direct and Indirect Effects of Alprazolam and Imipramine on α1-and α2-Adrenoceptors in Mouse Forebrain

  • 321
    Schubert, T.; Brunner, F.; Müller, W. E.:

    The Interaction of RS 86, a Centrally Acting m-Cholinoceptor Agonist with M1 and M2 Receptors in Rat Brain and Rat Heart, Respectively*

  • 324
    Pilch, H.; Müller, W. E.:

    Chronic Treatment with Piracetam Elevates Muscarinic Cholinergic Receptor Density in the Frontal Cortex of Aged Mice

  • 326
    Erfurth, A.; Reddington, M.; Schmauss, M.:

    Studies on Binding Sites for Adenosine Receptor Ligands in Rat Brain: An Approach to the Specification of Adenosinergic Functions

  • 329
    Hegerl, U.; Gaebel, W.; Ulrich, G.:

    Relationship Between Residual Symptomatology and Auditory Evoked Potentials in Schizophrenic Outpatients

  • 331
    Krieger, S.; Bertling, R.; Schweizer, A.; Tegeler, J.:

    Recording Automatic and Controlled Information Processing by Means of Bioelectrical Brain Signals in Normals and Paranoid Schizophrenics with and without Neuroleptic Medication

  • 334
    Mackert, A.; Woyth, C.; Flechtner, M.; Frick, K.:

    Increased Blink Rate in Acute and Remitted Schizophrenics

  • 336
    Hegerl, U.; Prochno, I.; Ulrich, G.; Müller-Oerlinghausen, B.:

    Are Auditory Evoked Potentials Suitable for Predicting the Response to Lithium Prophylaxis? - A study on the Effects of Repeated Measurement, Age, Gender, and Personality on the Amplitude/Stimulus Intensity Function in Healthy Volunteers*

  • 338
    Maurer, K.; Dierks, T.; Laux, G.; Rupprecht, R.; Ihl, R.:

    Topographic Mapping of EEG and Auditory Evoked P300 in Neuropsychopharmacology (Topographic Pharmaco-EEG and Pharmaco-AEP 300)

  • 343
    Ihl, R.; Maurer, K.; Dierks, T.; Wannemacher, W.:

    Effects of Pyritinol on the Distribution of Electrical Brain Activity

  • 346
    Reischies, F. M.; Gaebel, W.; Mielewczyk, A.; Frick, K.:

    Disturbed Eye Movements Guided by Visuospatial Cues in Schizophrenic Patients

  • 348
    Schulze, R. M.; Müller, W. E.; Gattaz, W. F.:

    A Radioenzymatic Assay for the Determination of Phospholipase A2 in Serum Suitable for Psychiatric and Non-Psychiatric Patients

  • 353
    Priebe, S.; Liesenfeld, O.; Müller-Oerlinghausen, B.:

    Resumption of Benzodiazepine Use After Withdrawal in Hospital - A Follow-up Study*

  • 355
    Barnas, C.; Fleischhacker, W. W.; Stuppäck, C.; Whiteworth, A. B.; Hinterhuber, H.:

    Investigation of Benzodiazepine-Consumers Concerning Intake-Habits,Signs of Abuse or Dependence, and Information About the Drug

  • 357
    Flechsenhar, K.; Müller, W. E.:

    Some Preliminary Data About the Properties of Tribulin, an Endogenous, Benzodiazepine Receptor Binding Inhibiting Compound from Human Urine

  • 360
    Martin, J. R.; Pieri, L.; Bonetti, E. P.; Schaffner, R.; Burkard, W. P.; Cumin, R.; Haefely, W. E.:

    Ro 16-6028: A Novel Anxiolytic Acting as a Partial Agonist at the Benzodiazepine Receptor

  • 365
    Meyer, J. W.; Woggon, B.; Küpfer, A.:

    Importance of Oxidative Polymorphism on Clinical Efficacy and Side-Effects of Imipramine - A Retrospective Study

  • 367
    UIrich, G.; Haug, H.-J.; Stieglitz, R.-D.; Fähndrich, E.:

    EEG Characteristics of Clinically Defined On-Drug-Responders and Non-Responders - A Comparison Clomipramine vs. Maprotiline

  • 369
    Stuppäck, Ch.; Schubert, H.; Barnas, Ch.; Mair, M.; Schifferle, I.; Unterweger, B.; Wörnhart, L.; Fleischhacker, W. W.; Hinterhuber, H.:

    First Results of an Open Phase II Study with the Antidepressant Paroxetine

  • 371
    Müller, W. E.; Bauer, K.; Rost, W.; Filser, J. G.; Fischer, M.; Gattaz, W. F.:

    Urinary MHPG-Sulfate and Urinary MHPG-Glucuronide, two Possible Markers of the Central or Peripheral Norepinephrine Metabolism in Man.The Effect of Alprazolam Treatment

  • 374
    Gattaz, W. F.; Bauer, K.; Rost, W.; Hübner, C. v K.; Müller, W. E.:

    Alprazolam Response in Major Depression: Relationship with Urinary Levels of MHPG-Sulfate

  • 376
    Frommberger, U.; Phllipp, M.; Maier, W.:

    The Influence of Medication on the Course of Major Depression: A 3-Year-Follow-Up with Polydiagnostic Measures

  • 378
    Laux, G.; Becker, T.; Kühne, G.; Lesch, K.-P.; Riederer, P.; Beckmann, H.:

    Clinical and Biochemical Effects of the Selective Phosphodiesterase Inhibitor Rolipram in Depressed Inpatients Controlled by Determination of Plasma Level

  • 380
    Phllipp, M.; Maier, W.:

    A Replication Study for the Prediction of Doxepine-Response in Depressed Outpatients

  • 381
    Filser, J. G.; Kaumeier, S.; Brand, T.; Schanz, H.; Terlinden, R.; Müller, W. E.:

    Pharmacokinetics of Amitriptyline and Amitriptylinoxide after Intravenous or Oral Administration in Humans

  • 387
    Gerbaldo, H.; Demisch, L.; Lehmann, C.-O.; Bochnik, J.:

    The Effect of OPC-4392, a Partial Dopamine Receptor Agonist on Negative Symptoms: Results of an Open Study

  • 389
    Olbrich, R.; Schanz, H.:

    The Effect of the Partial Dopamine Agonist Terguride on Negative Symptoms in Schizophrenics

  • 391
    Klieser, E.; StrauB, W. H.:

    Study to Establish the Indication for the Selective S2 Antagonist Ritanserin

  • 394
    Wetzel, H.; Heuser, I.; Benkert, O.:

    Benzodiazepines for Catatonic Symptoms, Stupor, and Mutism

  • 396
    Ruhland, M.; Krähling, H.; Fuchs, A.; Schön, U.:

    KC 9172* (Free Base of KC 7218) - An Antipsychotic/Anxiolytic Compound I. Antipsychotic and Anxiolytic Activity in Comparison with Chlorpromazine, Clozapine, Diazepam and Buspirone

  • 399
    Krähling, H.; Fuchs, A.; Ruhland, M.; Schön, U.; Mol, F.; Tulp, M.:

    KC 9172* (Free Base of KC 7218) - An Antipsychotic/Anxiolytic Compound II. Discrimiantion from Typical Neuroleptics and Benzodiazepine-like Minor Tranquilizers

  • 402
    Lesch, K. P.; Laux, G.; Pfüller, H.; Schulte, M.:

    Alpha-Adrenoceptor Function in Acute Paranoid Schizophrenia

  • 407
    Fähndrich, E.; Haug, H.-J.:

    Delusional Depression - A Distinct Illness?

  • 410
    Fey, P.; Pflug, B.; Jost, K.:

    Self-Rating of the Global State of Mood of Depressive Patients by a Bright-Dark-Scale

  • 412
    Stieglitz, R.-D.; Haug, H.-J.; Fähndrich, E.:

    Comparison Between Types of Diurnal Variations as Determined by Global Assessment and Daily Recordings of Mood

  • 414
    Fleischhauer, J.; Glauser, G.; Hofstetter, P.:

    The Influence of Light Therapy in Depressive Patients

  • 416
    Schlegel, Sabine; Maier, W.; Philipp, M.; Heuser, Isabella; Aldenhoff, J.:

    The Association between Psychopathological Aspects and CT Measurements in Affective Disorders

  • 418
    Haug, H.-J.; Fähndrich, E.:

    A Turning Point for Mood during Sleep Deprivation Therapy -does it Exist?

  • 420
    Demisch, L.; Gerbaldo, H.; Demisch, K.:

    Fluvoxamine-Melatonin-Stimulation-Test (FMST) in Patients with Depressive Disorders

  • 422
    Buller, R.; Maier, W.; Philipp, M.:

    Reliability of DSM-III Anxiety Disorders - Check-List Versus Structured Interview

  • 424
    Frommberger, U.; Philipp, M.; Maier, W.; Buller, R.; Klingler, T.:

    Prediction of Course in Major Depression. Does Psychopathology Predict Future Drug Intake or Relapse?

  • 426
    Volk, J.; Müller-Oerlinghausen, B.:

    Quality of Interepisodic Periods in Patients with Affective Disorders under Long-Term Lithium Treatment

  • 428
    Kasper, S.; Rogers, S. L.; Yancey, A. L.; Schulz, P. M.; Skwerer, R. G.; Rosenthal, N. E.:

    Phototherapy in Subsyndromal Seasonal Affective Disorder (S-SAD) and "Diagnosed" Controls

  • 430
    Lesch, K. P.; Laux, G.; Schulte, H. M.; Erb, A.; Pfüller, H.; Beckmann, H.:

    Pre- and Postsynaptic Alpha-Adrenergic Effects of Clonidine in Major Depressive Disorder

  • 432
    Carl, C.; Engelhardt, W.; Teichmann, G.; Fuchs, G.:

    Open Comparative Study with Treatment-Refractory Depressed Patients: Electroconvulsive Therapy - Anesthetic Therapy with Isoflurane (Preliminary Report)

  • 434
    van Calker, D.; Steber, R.; Greil, W.:

    Effects of Lithium Ions on the Metabolism of Inositol Phospholipids: Studies with Human Granulocytes

  • 436
    Fritze, J.; Koronakis, P.; Riederer, P.; Hekman, M.:

    Lymphocyte Adenylate Cyclase: A Model for Putative Adrenergic-Cholinergic Imbalances in Affective Disorders?

  • 438
    Rupprecht, R.; Rupprecht, Chr.; Rupprecht, M.; Noder, Monika; Schwarz, W.:

    Different Reactivity of the Hypothalamo-Pituitary-Gonadal-Axis in Depression and Normal Controls

  • 440
    Lesch, K.-P.; Laux, G.; Erb, A.; Pfüller, H.; Beckmann, H.:

    Neuroendocrine Regulation of Growth Hormone Secretion in Major Depressive Disorder

  • 443
    Neuhauser, H.; Laakmann, G.:

    Stimulation of Growth Hormone by GHRH as Compared to DMI in Depressed Patients

  • 445
    Hinz, A.; Laakmann, G.; Kropp, F.; Dick, G.:

    Influence of Growth Hormone Releasing Hormone (GHRH) on the Growth Hormone (GH) Secretion in Healthy Female and Male Subjects

  • 447
    Kohnen, R.; Oswald, W.-D.:

    The Effects of Valerian, Propranolol, and their Combination on Activation, Performance, and Mood of Healthy Volunteers under Social Stress Conditions

  • 451
    Stieglitz, R.-D.; Fähndrich, E.; Renfordt, E.:

    Interrater Study for the AMDP System

  • 453
    Huber, D.; Henrich, G.; Herschbach, P.:

    Measuring the Quality of Life: A Comparison between Physically and Mentally Chronically III Patients and Healthy Persons

  • 456
    Schönell, H.:

    Efficiency of the AMDP Anamnestic Data in Psychiatric Research

  • 458
    Albrecht, J.; Hedde, H. P.; Lundt, A.; Pittlik, V.; Stieglitz, R.; Baranowski, E.:

    Psychopathometrlcs in HIV-infected Patients - A Multimethodologic Study

  • 459
    Steinwachs, K. C.; Fehm, H. L.:

    Effects of the Neuropeptide PLG (L-Prolyl-leucyl-glycinamide) on Writing Pressure and Speed in Healthy Subjects

  • 461
    Huber, Dorothea:

    Combined and Separate Treatment Effects of Nicotine Chewing Gum and Self-Control Method

  • 463
    Hebenstreit, Marina; Buller, R.; Maier, W.; Philipp, M.; Frommberger, U.:

    The Personality Sphere in Patients with Panic Attacks

  • 465
    Philipp, M.; Delmo, Cynthia; Maier, W.; Buller, R.:

    The Use of Research Assistants in Polydiagnostic Research

    • Workshop I

  • 278
    Böcker, F. M.; Busch, H.; Feuerlein, W.; Mann, K.; Poser, W.; Rommelspacher, H.; Schied, H. W.; Thaden, A.:

    Projects of Biomedical Research on Alcoholism

    • Workshop II

  • 281
    Philipp, M.; Maier, W.; Buller, R.:

    Pharmacotherapy of Panic Attacks

    • Workshop III

  • 283
    Riederer, P.; Laux, G.; Beckmann, H.; Saletu, B.; Waldmeier, P.; Fritze, J.; DaPrada, M.; Möller, H. J.; Schmauss, M.; Przuntek, H.:

    The New Generation of Selective Monoamine Oxidase-lnhibitors: Biochemical, Pharmacological and Clinical Perspectives

    • Workshop IV

  • 285
    Möller, H. J.; Kissling, W.; Baumann, W.; Breyer-Pfaff, U.; Delini-Stula, A.; Holsboer, F.; Jungkunz, G.; Kuhs, H.; Laux, G.; Müller, W. E.; Müller-Oerlinghausen, B.; Schmauss, M.; Schönbeck, G.; Steiger, A.; Woggon, B.:

    Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities

    • Workshop V

  • 288
    Janke, W.; Kallus, W.; Netter, Petra:

    Psychopharmacological Acute Trials: Methodological Problems and Approaches for Solutions

    • Adverse Drug Reactions

  • 290
    Spieß-Kiefer, C.; Grohmann, R.; Schmidt, L. G.; Rüther, E.:

    Severe and Life-Threatening Adverse Reactions to Psychotropic Drugs

    • Effects of Psychotropic Drugs:Models in Animals

  • 312
    Coward, D. M.; Dixon, A. K.; Urwyler, S.; Vigouret, J.-M.:

    Pharmacological Properties of SDZ 208-912: A Potential High Potency,Non-Classical Neuroleptic

    • Benzodiazepines

  • 350
    Pohl, J.; Janke, W.; Erdmann, G.; Capek, D.:

    The Problem of Influencing Specific or Unspecific Emotional States by Drugs: Effects of a Tranquilizer and Two Beta-Blocking Agents under Noise Conditions

    • Antidepressant Drugs

  • 363
    Möller, H. J.; Haug, G.:

    Secondary and Meta-Analysis of the Efficacy of Non-Tricyclic Antidepressants

    • Therapy of Schizophrenia

  • 384
    Gaebel, W.; Pletzcker, A.; Ulrich, G.; Schley, J.; Müller-Oerlinghausen, B.:

    Predictors of Neuroleptic Treatment Response in Acute Schizophrenia: Results of a Treatment Study with Perazine

    • Depression:Models and Methods in Clinical Research

  • 404
    Kaschka, W. P.; Thürauf, N.; Mokrusch, Th.; Korth, M.:

    Electrooculography and Dark Adaptation in Patients with Affective and Schizoaffective Psychoses: Early Physiological Effects of Carbamazepine and Lithium

    • Psychopayhometry

  • 449
    Maier, W.; Philipp, M.; Buller, R.; Schlegel, S.:

    Reliability and Validity of the Assessment of Antidepressant Effects